SCHEMBL2477555

SCHEMBL2477555

CC(C)(C)OC(=O)Nc1ccccc1NC(=O)c1ccc(C(CCCN2CCOCC2)NC(=O)Nc2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD274 Q9NZQ7 1/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2D6 P10635 1/20 0.47
ALDH1A1 P00352 5/20 0.45
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
KDM4E B2RXH2 1/20 0.45
MAPK1 P28482 1/20 0.45
AVPR1A P37288 1/20 0.45
MAPT P10636 4/20 0.43
LMNA P02545 2/20 0.42
GAA P10253 1/20 0.42
TACR2 P21452 2/20 0.40
EPHX2 P34913 1/20 0.40
ABCG2 Q9UNQ0 2/20 0.40
CYP3A4 P08684 1/20 0.39
HPGD P15428 1/20 0.39
ABCB1 P08183 1/20 0.39
BCL2 P10415 1/20 0.39
BECN1 Q14457 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3833732 0.87 HDAC1 (0.51) CYP2C9CYP2D6ALDH1A1KMT2AMEN1
SCHEMBL2477762 0.86 CD274 (0.45) CD274ALDH1A1KDM4EMAPTGAA
SCHEMBL3832883 0.85 MEN1 (0.39) CD274CYP2C9CYP2D6ALDH1A1KMT2A
SCHEMBL2474232 0.85 NAMPT (0.47) CD274ALDH1A1LMNAGAAEPHX2
SCHEMBL2474768 0.85 UTS2R (0.44) ALDH1A1KMT2AMAPTABCG2
SCHEMBL2474155 0.83 CD274 (0.42) CD274TACR2EPHX2ABCG2ABCB1
SCHEMBL2476095 0.82 CD274 (0.47) CD274ALDH1A1KDM4EGAATACR2
SCHEMBL2477400 0.82 CYP2D6 (0.48) CD274CYP2D6ALDH1A1KMT2AMEN1
SCHEMBL2477763 0.81 POLB (0.47) CD274ALDH1A1KDM4EGAATACR2
SCHEMBL10476433 0.81 CD274 (0.46) CD274CYP2D6TACR2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
EP-2107052-B1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2011-10-12 EP disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2107052-A1 NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2009-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 CD274 4808/4885CYP2C9 4579/4885CYP2D6 4419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.